Karyopharm Therapeutics Inc. (KPTI) stock
KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
$0.04−0.01 (-20.00%)
Close on Nov 9, 2026Market cap $1.16KP/E –Yield –
Karyopharm Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Karyopharm Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $146.62M, up 6.8% year over year. For fiscal 2025 it was $146.07M, up 0.6% from the year before. Over ten years it grew 89.1% a year on average. The highest annual figure on record is $209.82M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.07M | +0.6% |
| FY2024 | Dec 31, 2024 | $145.24M | -0.5% |
| FY2023 | Dec 31, 2023 | $146.03M | -7.0% |
| FY2022 | Dec 31, 2022 | $157.07M | -25.1% |
| FY2021 | Dec 31, 2021 | $209.82M | +94.1% |
| FY2020 | Dec 31, 2020 | $108.09M | +164.3% |
| FY2019 | Dec 31, 2019 | $40.89M | +34.8% |
| FY2018 | Dec 31, 2018 | $30.34M | +1790.1% |
| FY2017 | Dec 31, 2017 | $1.61M | +942.2% |
| FY2016 | Dec 31, 2016 | $154.00K | -38.4% |
| FY2015 | Dec 31, 2015 | $250.00K | +9.2% |
| FY2014 | Dec 31, 2014 | $229.00K | -40.8% |
| FY2013 | Dec 31, 2013 | $387.00K | -39.0% |
| FY2012 | Dec 31, 2012 | $634.00K | +317.1% |
| FY2011 | Dec 31, 2011 | $152.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $33.43M | -11.9% |
| Q1 FY2026 | Mar 31, 2026 | $35.07M | +16.8% |
| Q4 FY2025 | Dec 31, 2025 | $34.08M | +11.6% |
| Q3 FY2025 | Sep 30, 2025 | $44.04M | +13.6% |
| Q2 FY2025 | Jun 30, 2025 | $37.93M | -11.4% |
| Q1 FY2025 | Mar 31, 2025 | $30.02M | -9.4% |
| Q4 FY2024 | Dec 31, 2024 | $30.54M | -9.5% |
| Q3 FY2024 | Sep 30, 2024 | $38.78M | +7.7% |
| Q2 FY2024 | Jun 30, 2024 | $42.79M | +13.9% |
| Q1 FY2024 | Mar 31, 2024 | $33.13M | -14.4% |
| Q4 FY2023 | Dec 31, 2023 | $33.75M | +0.5% |
| Q3 FY2023 | Sep 30, 2023 | $36.01M | -0.4% |
| Q2 FY2023 | Jun 30, 2023 | $37.58M | -5.3% |
| Q1 FY2023 | Mar 31, 2023 | $38.70M | -18.8% |
| Q4 FY2022 | Dec 31, 2022 | $33.58M | -73.4% |
| Q3 FY2022 | Sep 30, 2022 | $36.15M | -4.1% |
| Q2 FY2022 | Jun 30, 2022 | $39.68M | +75.6% |
| Q1 FY2022 | Mar 31, 2022 | $47.67M | +104.9% |
| Q4 FY2021 | Dec 31, 2021 | $126.27M | +259.7% |
| Q3 FY2021 | Sep 30, 2021 | $37.69M | +76.7% |
| Q2 FY2021 | Jun 30, 2021 | $22.60M | -32.6% |
| Q1 FY2021 | Mar 31, 2021 | $23.26M | +28.2% |
| Q4 FY2020 | Dec 31, 2020 | $35.10M | +94.0% |
| Q3 FY2020 | Sep 30, 2020 | $21.33M | +62.2% |
| Q2 FY2020 | Jun 30, 2020 | $33.51M | +253.0% |
| Q1 FY2020 | Mar 31, 2020 | $18.14M | +11601.9% |
| Q4 FY2019 | Dec 31, 2019 | $18.10M | +8684.5% |
| Q3 FY2019 | Sep 30, 2019 | $13.15M | +5401.7% |
| Q2 FY2019 | Jun 30, 2019 | $9.49M | -52.3% |
| Q1 FY2019 | Mar 31, 2019 | $155.00K | -98.5% |
| Q4 FY2018 | Dec 31, 2018 | $206.00K | -86.6% |
| Q3 FY2018 | Sep 30, 2018 | $239.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $19.89M | +662933.3% |
| Q1 FY2018 | Mar 31, 2018 | $10.00M | +14605.9% |
| Q4 FY2017 | Dec 31, 2017 | $1.53M | +3163.8% |
| Q3 FY2017 | Sep 30, 2017 | $0 | -100.0% |
| Q2 FY2017 | Jun 30, 2017 | $3.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $68.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $47.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $48.00K | – |
See a number that looks wrong?